ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1370

A Delayed Effect of Tumor Necrosis Factor Inhibitors on Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort

Denis Poddubnyy1, Valeria Rios Rodriguez2, Murat Torgutalp2, Ani Dilbaryan2, Maryna Verba2, Mikhail Protopopov2, Fabian Proft2, Judith Rademacher2, Hildrun Haibel2, Joachim Sieper2 and Martin Rudwaleit3, 1Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany

Meeting: ACR Convergence 2020

Keywords: ,

Session Information

Date: Sunday, November 8, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: There are inconclusive data on the effect of tumor necrosis factor inhibitors (TNFi) on radiographic spinal progression in axial spondyloarthritis (axSpA). Although inflammation and new bone formation are linked in axSpA, TNFi failed to show inhibition of radiographic spinal progression over two years compared to historical cohorts in pivotal studies in radiographic axSpA. Subsequent observational studies suggested that a longer treatment duration, earlier treatment initiation and effective inflammation suppression might be required to achieve inhibition of radiographic progression.

The aim of the current study was to evaluate the effect of TNFi on radiographic spinal progression in patients with early axSpA in a long-term inception cohort.

Methods: A total of 266 patients with early axSpA (with r-axSpA with symptom duration ≤10 years and nr-axSpA with symptom duration ≤5 years) from the German Spondyloarthritis Inception Cohort (GESPIC) with at least two sets of spinal radiographs obtained at least 2 years apart during a 10-year follow-up were included. These patients contributed with a total of 542 2-year radiographic intervals. Spinal radiographs were evaluated by three trained and calibrated readers according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). The final mSASSS was calculated as a mean of three reader scores.  The association between the current TNFi, previous TNFi and radiographic spinal progression defined as the absolute mSASSS change score over 2 years was analyzed using longitudinal generalized estimating equations (GEE) analysis.

Results: Only 9 patients were treated with a tumor necrosis factor inhibitor (TNFi) at baseline, and a total of 77 patients received TNFi during the entire follow-up period that gave 103 2-year intervals covered by TNFi of any duration, and 78 intervals covered by TNFi with treatment duration of at least 12 months. Radiographic spinal progression in axSpA patients receiving TNFi in the current 2-year interval was not different from progression in patients not treated with TNFi, while TNFi in the previous 2-year interval was associated with lower progression compared to patients without TNFi in this interval (Figures 1 and 2). The latter was also evident for patients who received TNFi in both previous and current 2-year intervals, i.e. patients treated with TNFi over 4 years. The longitudinal GEE analysis confirmed no significant association between current TNFi treatment and radiographic spinal progression but a significant association between TNFi in the previous 2-year interval (especially if this was continued also in the current interval giving 4 years in total) and the progression in the current one (Table).

Conclusion: TNFi treatment exhibits a delayed inhibitory effect on radiographic spinal progression in axSpA that becomes evident after 4 years of treatment.

Disclosure: D. Poddubnyy, Eli Lilly and Company, 2, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, BioCad, 5, Gilead, 5, GSK, 5, UCB, 5, 8, BMS, 8; V. Rios Rodriguez, None; M. Torgutalp, None; A. Dilbaryan, None; M. Verba, None; M. Protopopov, None; F. Proft, Novartis, 2, 8, AbbVie, 8, AMGEN, 8, BMS, 8, Hexal, 8, Celgene, 8, Lilly, 8, MSD, 8, Pfizer, 8, Roche, 8, UCB, 8; J. Rademacher, None; H. Haibel, None; J. Sieper, AbbVie, 5, Novartis, 5, 8, Lilly, 8, Janssen, 5, Merck, 5, 8; M. Rudwaleit, Bristol-Myers Squibb, 5, 8, Chugai Pharmaceutical Co., Ltd., 5, 8, Eli Lilly and Company, 5, 8, Janssen, 5, 8, Novartis, 5, 8, UCB Pharma, 5, 8, AbbVie, 5, 8, Pfizer, 5, 8, Celgene, 8, Roche, 5, 8, Merck Sharp & Dohme, 5, 8.

To cite this abstract in AMA style:

Poddubnyy D, Rios Rodriguez V, Torgutalp M, Dilbaryan A, Verba M, Protopopov M, Proft F, Rademacher J, Haibel H, Sieper J, Rudwaleit M. A Delayed Effect of Tumor Necrosis Factor Inhibitors on Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/a-delayed-effect-of-tumor-necrosis-factor-inhibitors-on-radiographic-spinal-progression-in-patients-with-axial-spondyloarthritis-long-term-results-from-the-german-spondyloarthritis-inception-cohort/. Accessed .

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-delayed-effect-of-tumor-necrosis-factor-inhibitors-on-radiographic-spinal-progression-in-patients-with-axial-spondyloarthritis-long-term-results-from-the-german-spondyloarthritis-inception-cohort/